Aptevo Therapeutics Inc. - 10-Q Filing

Aptevo Therapeutics reports Q3 2026 financial results featuring significant equity-based activity including Niowave warrants and standby equity purchase agreements.

SEC EDGAR ·

Tickers: $APVO

Read the full article at SEC EDGAR

More Regulatory news